Floatz logo

Cetuximab-Irdye800

High-grade Glioma

University Medical Center GroningenPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

108 Active assets in the High-grade Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Cetuximab-Irdye800 is also rated in:

pancreatic adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
rectal carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →